Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase 3, Multicenter, Randomized, Efficacy Accessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Failed Anti-TNF therapy
This study will compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease who have failed anti-TNF therapy.
Confirmed diagnosis of CD for at least 3 months Demonstrated intolerance or inadequate response to one or more anti TNF therapies Laboratory values meeting protocol criteria CDAI score of 220-450 at Baseline
Exclusion Criteria:
No history of UC No known complications of CD No systematic bowel strictures No history of malignancy No history of allergic reactions to the products in the same class